Italia markets close in 2 hours

FTSE MIB
33.437,83
-269,38(-0,80%)
Dow Jones
39.112,16
-299,05(-0,76%)
Nasdaq
17.717,65
+220,84(+1,26%)
Nikkei 225
39.667,07
+493,92(+1,26%)
Petrolio
80,89
+0,06(+0,07%)
Bitcoin EUR
57.661,04
+295,52(+0,52%)

NBIX Mar 2025 145.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

17,85

0,00

(0,00%)

In data: 12:16PM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat